Paclitaxel Poliglumex | CAS#263351-82-2

MedKoo Cat#: 597118 | Name: Paclitaxel Poliglumex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Paclitaxel Poliglumex is a bioconjugate in which paclitaxel is linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.

Chemical Structure

Paclitaxel Poliglumex

CAS#263351-82-2 (Poliglumex)

Theoretical Analysis

MedKoo Cat#: 597118

Name: Paclitaxel Poliglumex

CAS#: 263351-82-2 (Poliglumex)

Chemical Formula: C52H60N2O18

Exact Mass: 0.0000

Molecular Weight: 1001.04

Elemental Analysis: C, 62.39; H, 6.04; N, 2.80; O, 28.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

186040-50-6 (ceribate) 33069-62-4 (free base) 263351-82-2 (Poliglumex) Paclitaxel-SMCC 117527-50-1 (Paclitaxel-Succinic acid) Paclitaxel-MVCP

Synonym

Paclitaxel Poliglumex; PG-TXL; PPX; CT 2103; CT-2103; CT2103; Opaxio; Xyotax; paclitaxel-polyglutamate polymer; polyglutamate paclitaxel; polyglutamic acid paclitaxel; Poly-L-Glutamic acid-Paclitaxel Conjugate;

IUPAC/Chemical Name

(2aS,4S,4aS,6R,9S,11R,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate L-glutamate

InChi Key

ZPUHVPYXSITYDI-ZYOSQDPASA-N

InChi Code

InChI=1S/C47H51NO14.C5H9NO4/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5;6-3(5(9)10)1-2-4(7)8/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54);3H,1-2,6H2,(H,7,8)(H,9,10)/t31-,32-,33-,35-,36+,37+,38-,40-,45+,46-,47-;3-/m00/s1

SMILES Code

CC([C@@H](OC([C@H](O)[C@@H](NC(c1ccccc1)=O)c2ccccc2)=O)C3)=C([C@H]4OC(C)=O)C(C)(C)[C@@]3(O)[C@@H](OC(c5ccccc5)=O)[C@@H]6[C@]7(OC(C)=O)CO[C@H]7C[C@H](O)[C@@]6(C)C4=O.O=C(O)[C@@H](N)CCC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,001.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Markovsky E, Eldar-Boock A, Ben-Shushan D, Baabur-Cohen H, Yeini E, Pisarevsky E, Many A, Aviel-Ronen S, Barshack I, Satchi-Fainaro R. Targeting NCAM-expressing neuroblastoma with polymeric precision nanomedicine. J Control Release. 2017 Mar 10;249:162-172. doi: 10.1016/j.jconrel.2017.01.044. Epub 2017 Feb 1. PubMed PMID: 28159518. 2: Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247. PubMed PMID: 26658237. 3: Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade. JAMA Dermatol. 2015 Nov;151(11):1226-9. doi: 10.1001/jamadermatol.2015.2554. PubMed PMID: 26375166. 4: Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156. PubMed PMID: 25436828. 5: Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW, Ying W. A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. Int J Med Sci. 2014 Mar 18;11(5):479-87. doi: 10.7150/ijms.8340. eCollection 2014. PubMed PMID: 24688312; PubMed Central PMCID: PMC3970101. 6: Muggia F, Kudlowitz D. Novel taxanes. Anticancer Drugs. 2014 May;25(5):593-8. doi: 10.1097/CAD.0000000000000053. Review. PubMed PMID: 24374330. 7: Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella T, Dipetrillo T, Evans D, Elinzano H, Constantinou M, Stopa E, Puthawala Y, Cielo D, Santaniello A, Oyelese A, Mantripragada K, Rosati K, Isdale D, Safran H; Brown University Oncology Group Study. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. Am J Clin Oncol. 2014 Oct;37(5):444-9. doi: 10.1097/COC.0b013e31827de92b. PubMed PMID: 23388562. 8: Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA; North Central Cancer Treatment Group. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol. 2014 Apr;37(2):167-71. doi: 10.1097/COC.0b013e31826e0550. PubMed PMID: 23211220; PubMed Central PMCID: PMC3593738. 9: Raghavan D, Boxerman J, Jeyapalan S, Rogg J. Radiation necrosis of a high-grade glioma. Med Health R I. 2012 May;95(5):159-60. PubMed PMID: 22808637. 10: Seamon LG, Richardson DL, Copeland LJ. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar;55(1):131-55. doi: 10.1097/GRF.0b013e318248050d. Review. PubMed PMID: 22343234. 11: Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15;17(22):7183-93. doi: 10.1158/1078-0432.CCR-11-0981. Epub 2011 Oct 5. PubMed PMID: 21976532; PubMed Central PMCID: PMC5723083. 12: Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JB, Manunta S, Mazzarella L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol. 2012 Mar;23(3):547-55. doi: 10.1093/annonc/mdr382. Epub 2011 Sep 6. Review. PubMed PMID: 21896541. 13: Galic VL, Wright JD, Lewin SN, Herzog TJ. Paclitaxel poliglumex for ovarian cancer. Expert Opin Investig Drugs. 2011 Jun;20(6):813-21. doi: 10.1517/13543784.2011.576666. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Investig Drugs. 2012 Jul;21(7):1067. PubMed PMID: 21470062. 14: Nemunaitis J, Senzer N, Cooper B, Nemunaitis M, Bedell C, Singer JW, Oldham FB. Procoagulant inhibitory properties of paclitaxel poliglumex. Int J Gen Med. 2010 Dec 15;4:5-11. doi: 10.2147/IJGM.S12170. PubMed PMID: 21403785; PubMed Central PMCID: PMC3056324. 15: Eldar-Boock A, Miller K, Sanchis J, Lupu R, Vicent MJ, Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials. 2011 May;32(15):3862-74. doi: 10.1016/j.biomaterials.2011.01.073. Epub 2011 Mar 4. PubMed PMID: 21376390; PubMed Central PMCID: PMC3857101. 16: Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarano R, Burrows W, Safran H. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2012 Feb;35(1):64-7. doi: 10.1097/COC.0b013e318201a126. PubMed PMID: 21297434. 17: Van S, Das SK, Wang X, Feng Z, Jin Y, Hou Z, Chen F, Pham A, Jiang N, Howell SB, Yu L. Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine. 2010 Oct 21;5:825-37. doi: 10.2147/IJN.S13482. PubMed PMID: 21042550; PubMed Central PMCID: PMC2964040. 18: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. doi: 10.1358/mf.2010.32.6.1538165. PubMed PMID: 20852754. 19: Zhang SQ, Song YN, He XH, Zhong BH, Zhang ZQ. Liquid chromatography-tandem mass spectrometry for the determination of paclitaxel in rat plasma after intravenous administration of poly(L-glutamic acid)-alanine-paclitaxel conjugate. J Pharm Biomed Anal. 2010 Apr 6;51(5):1169-74. doi: 10.1016/j.jpba.2009.11.030. Epub 2009 Dec 4. PubMed PMID: 20036092. 20: Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010 Apr;21(4):433-8. doi: 10.1097/CAD.0b013e3283355211. PubMed PMID: 20016365.